# Clinical Trial of TB511 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06400160/  
OnCo record `nct06400160` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of pembrolizumab in colorectal cancer, run by Twinpig Biolab, Inc., not yet recruiting.

## Summary

Clinical Trial of TB511 in Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT06400160 by Twinpig Biolab, Inc., with a registry enrolment figure of 12 participants, started 2026-03 and due to reach its primary completion in 2027-03. Interventions recorded: TB511; Keytruda. Conditions listed: NSCLC; Prostate Cancer; Colorectal Cancer; Hepatocellular Carcinoma. Primary outcome: Phase I Clinical trial-Maximum tolerated dose (MTD).; Phase I Clinical trial-Recommended Phase IIa dose (RP2D).; Phase IIa Clinical trial-anti-tumor effect-to evaluate the Objective response rate (ORR) of TB511 monotherapy and combination therapy with Pembrolizumab in patients with advanced solid tu. Colorectal eligibility wording from the registry: "* Documented irreversible surgical sterilization by hysterectomy, dual ovariectomy, or oophorectomy (tubal litigation does not satisfy this criteria)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06400160
- Phase: 1/2
- Setting: An Open-label, Multi-center, and Dose-escalation, Phase 1/2a Clinical Trial to Assess the Maximum Tolerated Dose(MTD), Safety, and the Anti-tumor Effect of TB511 Monotherapy in Patients With Advanced Solid Tumors Refractory or Intolerant to Standard of Care(SoC) and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors Relapsed or Refractory
- Sponsor: Twinpig Biolab, Inc.
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT06400160: https://clinicaltrials.gov/study/NCT06400160

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06400160.json